Nebilet (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebilet, is a beta blocker presented as a tablet for oral use. It treats hypertension and heart failure in adult patients.

GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebilet is a selective β1‑adrenergic blocker used in cardiovascular conditions that require blood‑pressure control and cardiac support.

Hypertension: lowers systolic and diastolic pressure, reducing cardiovascular risk. Heart failure with reduced ejection fraction: improves ventricular function and decreases hospitalization. Left ventricular dysfunction: enhances cardiac output and mitigates symptoms of chronic heart disease.

Nebilet may cause a range of adverse reactions, which are categorised by frequency.

Common Side Effects: - Headache - Dizziness or light‑headedness - Fatigue or tiredness - Bradycardia (slow heart rate) - Nasal congestion - Peripheral edema

Serious or Rare Side Effects: - Severe bradycardia or heart block - Bronchospasm, especially in patients with asthma - Allergic reactions such as rash or angio‑edema - Hepatic enzyme elevation - Acute heart failure decompensation

Before initiating Nebilet, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check regularly to avoid hypotension. - Cardiac assessment: review heart rate and conduction abnormalities. - Asthma or chronic obstructive pulmonary disease: use with caution due to possible bronchospasm. - Renal impairment: dose adjustment may be required. - Discontinuation: avoid abrupt withdrawal; taper under medical supervision. - Store at room temperature: keep in the original pack, protect from moisture.

Nebilet can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Other β‑blockers or non‑selective β‑blockers: additive cardiac depression. - Calcium‑channel blockers verapamil or diltiazem: increased risk of AV‑block and bradycardia. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may raise nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: may potentiate hypotensive effect. - ACE inhibitors or ARBs: monitor for excessive blood‑pressure reduction. - NSAIDs: can blunt antihypertensive response. - Anti‑arrhythmic agents (e.g., amiodarone): watch for conduction disturbances. - Antidiabetic drugs: monitor glucose control as β‑blockade may mask hypoglycaemia symptoms.